1. Academic Validation
  2. Regulation of angiogenesis and cancer cell proliferation by human vault RNA1-2

Regulation of angiogenesis and cancer cell proliferation by human vault RNA1-2

  • NAR Cancer. 2025 Aug 30;7(3):zcaf028. doi: 10.1093/narcan/zcaf028.
Stefano Gallo 1 2 Anastasiia Suspitsyna 1 2 Daniel Sanchez-Taltavull 3 Rafael Sebastián Fort 4 5 Maria Ana Duhagon 6 Deborah Stroka 3 Norbert Polacek 1
Affiliations

Affiliations

  • 1 Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland.
  • 2 Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.
  • 3 Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • 4 Sección Genómica Funcional, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay.
  • 5 Departamento de Genómica, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo 11600, Uruguay.
  • 6 Unidad Académica de Genética, Facultad de Medicina, Universidad de la República, Montevideo 11800, Uruguay.
Abstract

Noncoding RNAs play pivotal roles in tumorigenesis and Cancer progression. Recent evidence has identified vault RNAs (vtRNAs) as critical regulators of cellular homeostasis. The human genome encodes four vtRNA paralogs, which are differentially expressed in Cancer tissues and contribute to tumor development. The best studied vtRNA1-1 is involved in regulating Apoptosis resistance, Autophagy, lysosomal biogenesis, and drug resistance. Here, we present the first comprehensive characterization of vtRNA1-2 using a knockout hepatocellular carcinoma (HCC) cell line. Loss of vtRNA1-2 impaired Cancer cell viability and proliferation by modulating mitogen-activated protein kinase signaling. Additionally, vtRNA1-2-deficient cells exhibited reduced motility and a decreased invasive potential. Unlike vtRNA1-1, vtRNA1-2 did not influence Autophagy or lysosomal activity. Instead, vtRNA1-2 is implicated in the regulation of angiogenesis, a key process in tumor progression. VTRNA1-2-promoter hypomethylation is correlated with chromatin accessibility in liver Cancer samples and we uncovered an association between promoter methylation and key patient clinical conditions as registered in the TCGA metadata. These findings highlight a distinct oncogenic role for vtRNA1-2 in HCC and suggest that it may serve as a potential therapeutic target. Our study underscores the functional divergence among vtRNA paralogs, supporting the concept that each exerts unique biological effects rather than acting as redundant molecular entities.

Figures
Products